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Obesity and excessive gestational weight gain (GWG) in
pregnancy result in adverse maternal and fetal outcomes
and significant health costs.1–3 Compared with normal
weight women, obese women are at increased risk for
pregnancy loss, gestational diabetes, preeclampsia, and still-
birth,1,2,4,5 and their infants are at increased risk of macro-
somia, being large for gestational age, birth trauma,
childhood obesity, andmetabolic syndrome.6–9 In preclinical
animal models, dam consumption of a high-fat diet (HFD)






Abstract Objective This study was aimed to measure the effects of a high-fat diet and
metformin on placental mechanistic target of rapamycin (mTOR) signaling in mice.
Study Design Pregnant friend virus B (FVB)-strain mice were allocated on embryonic
day (e) 0.5 to one of four groups; group 1: control diet (CD, 10% fat) þ control
treatment (CT), group 2: CD þ metformin treatment (MT), group 3: high-fat diet (HFD,
60% fat) þ CT, and group 4: HFD þ MT. Metformin (2.5mg/mL) was provided in water;
CT mice received water. Fetuses and placentas were collected. Western blot measured
placental p-Akt and p-S6 expression.
Results 20dams (five/group) and192 fetuseswere studied. ComparedwithCD-fed,HFD-
fed dams had higher placental p-Akt protein expression (p < 0.0001). Among HFD-dams,
placental p-Akt was higher in metformin-treated compared with control-treated
(p < 0.001). Among CD-fed dams, there was no significant difference in placental p-S6
expression in MT versus CT groups. Among HFD-fed dams placental p-S6 expression was
lower in those exposed to metformin-treated versus controls (p ¼ 0.001).
Conclusion Increased placental mTOR signaling and metformin inhibition of placen-
tal mTOR signaling only occurred in the presence of an HFD exposure. These findings
suggest that metformin may modulate placental mTOR signaling in the presence of
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inflammation, and altered maternal and fetal metabolic
programming.10–12 In human studies, obese women are
more likely to have excessive GWG which makes it difficult
to separate the effects of baseline maternal obesity from the
effects of excessiveGWGonoffspring birthweight,metabolic
programming, and adverse maternal or infant outcomes.
The increase in the prevalence of both maternal obesity
and excessive GWG and their deleterious fetal effects have
led researchers to seek interventions to limit excess mater-
nal weight gain, fetal overgrowth, and adverse fetal meta-
bolic programming. One such intervention tested is
metformin, a biguanide oral hypoglycemic agent used as a
first-line agent to treat type II diabetes mellitus.13 In addi-
tion to its glucose-lowering effects, metformin reduces
weight gain, systemic inflammation, and inhibits the
mechanistic target of rapamycin (mTOR) pathway, a nutri-
ent-sensing protein complex implicated in diseases where
growth and homeostasis are compromised, such as obesity,
cancer, and diabetes.14–17 mTOR functions as a part of two
protein signaling complexes, mTORC1 and mTORC2.
mTORC1 is activated by growth factors such as insulin via
the insulin/Akt pathway (►Fig. 1). Activation of mTORC1
results in phosphorylation of S6 (p-S6) which subsequently
results in cellular translation and cell growth.18 Metformin
is thought to inhibit mTORC1.19 We previously reported
that when pregnant mice were exposed to an HFD during
pregnancy, they gained more weight and had heavier
fetuses compared with those fed a control diet (CD).20 In
our model, metformin attenuated fetal weight gain in HFD-
fed dams compared with dams fed a control diet. While its
ability to inhibit mTOR pathway signaling in animal tissues
and numerous cancers have been well-described,19,21–23
metformin’s effect on placental mTOR is unknown. Placen-
tal mTOR inhibition may be a mechanism by which met-
formin attenuates fetal weight gain. Our objective was to
measure the effects of an HFD with and without concomi-
tant metformin exposure on placental mTOR signaling. We
hypothesized that among HFD-dams, metformin inhibits
placental mTOR signaling among placentas exposed to a




The Institutional Animal Care and Use Committee (IACUC) at
our institution approved this protocol (15–163.0) and all
experimental animals were maintained in accordance with
the IACUC and the National Institutes of Health (NIH) guide
for the care and use of laboratory animals.
Our model has been described in detail previously.20
Briefly, female FVB (friend virus B)-strain mice (n ¼ 20)
were weighed and then bred with control FVB males. On
embryonic day (e) 0.5 (defined upon the detection of a
vaginal plug) pregnant dams were allocated into one of
four diet and treatment groups (n ¼ 5 dams per group);
group 1: CD (10% calories from fat, Research Diets, New
Brunswick, NJ) þ control treatment (CT, water). Group 2:
CD þ metformin (MT) in water (2.5 mg/mL).24,25 Group 3:
HFD (60% calories from fat, Research Diets, New Brunswick,
NJ) þ CT. Group 4: HFD þ MT in water (2.5 mg/mL). All
groups were fed ad libitum until euthanasia.
On e17.5 dams were anesthetized with ketamine and the
dams were euthanized via cervical dislocation. Fetuses and
placentas were immediately removed from the uterine
horns, weighed, and frozen at 80°C.
Fig. 1 Model illustrating mTOR signaling. IGF, insulin-like growth factor; IRS1, insulin receptor substrate 1; PI3K, phosphoinositide 3-kinase;
TSC1/2, tuberous sclerosis 1 and tuberous sclerosis 2; Rheb, rhas homolog enhanced in brain; mTORC1/2, mechanistic target of rapamycin
complex 1 and 2; S-6K, S-6 kinase; 4EBP1, eukaryotic translation initiation factor 4e binding protein 1.
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Western Blot
Five placentas selected from each treatment group (one per
treatment dam) were prepared in Tissues PE LB buffer þ
PhosStop following manufacturer instructions. Lysate pro-
tein concentrations were measured using a BCA Protein
Assay Kit (Pierce, Rockford, IL). Equal amount of protein
(50 µg) was separated by gel electrophoresis and transferred
onto a PVDFmembrane. Themembranewas blockedwith 5%
nonfat drymilk and then incubatedwith a 1:1,000 dilution of
primary antibody (phos-Akt and phos-S6-kinase, Cell Signal-
ing Technology, Danvers, MA) overnight at 4°C. We selected
phos-Akt and phos-S6 kinase because phos-Akt expression
provides insight into upstreamactivation and feedbackof the
mTOR pathway and phos-S6 kinase provides insight into
downstream activation of the pathway (►Fig. 1).26,27 The
membranewas thenwashed and incubatedwith a secondary
peroxidase conjugated antibody for 1 hour after washing.
Antibody binding was detected using an enhanced chemilu-
minescence detection buffer by Alpha Innotech imaging
system (San Leandro, CA). All blots were stripped and
reprobed with pan-Akt, pan-S6-k, and either anti-α-tubulin
or anti-β-actin. Blots were imaged and densities were mea-
sured using Image Laboratory software (Bio-Rad Labora-
tories, Inc., Hercules, CA). Western blot results are reported
as relative expression (compared with the reference protein
α-tubulin or β-actin). Analyses were performed using STATA
version 14.2 (College Station, TX). Analysis of variance
(ANOVA) and pairwise Student’s t-tests were used to com-
pare continuous parametric outcomes. A p-value of < 0.05
was considered significant.
Results
Characteristics of the dams, fetuses, andplacentas in the study
are reported in►Table 1. Dammeanstartingweight, litter size,
and placenta weight were not significantly different among
treatmentgroups.Wehavepreviously reported that compared
with control diet-fed dams (group 1), HFD-fed dams (group 3)
gained significantly more weight during pregnancy. Among
HFD-fed dams, there were no significant differences in dam
weight gain between control (group 3) andmetformin-treated
dams (group 4). Additionally, compared with control diet-fed
dams (group 1), HFD-fed dams (group 3) had significantly
heavier. In HFD-fed dams, compared with control-treated
(group 3), the metformin-treated (group 4) had significantly
lower fetal weight. Neeta Reference.
►Fig. 2 shows placental p-Akt Western blot results by
treatment group. Compared with CD-fed dams, HFD-fed
dams had significantly higher placental p-Akt protein
expression (p < 0.001). Metformin did not decrease placen-
tal p-Akt expression amongHFD-fed dams. Rather, compared
with control-treated dams receiving an HFD, placental Akt
was significantly higher in metformin-treated dams receiv-
ing an HFD (p ¼ 0.004).
►Fig. 3 shows placental p-S6 western blot results. Among
CD-fed dams, there was no significant difference in placental
p-S6 expression inmetformin versus control-treated groups.
Among HFD-fed dams; however, placental p-S6 expression
was lower in those exposed to metformin versus control
(p ¼ 0.001).
Comment
In ourmousemodel,we found that feeding pregnant dams an
HFD increased placental expression of p-Akt, an activity
marker of the nutrient-sensing pathway mTOR. We also
found that in-utero metformin exposure attenuated HFD-
induced placental p-Akt expression, and decreased placental
p-S6 expression.
Wechose to lookat placentalproteinconcentrationsofp-S6
and p-Akt as they represent markers of mTORC1 activity and
signaling. P-S6 is often used as a downstream marker of
mTORC1 activity since it is specifically phosphorylated by
mTORC1 both in vitro and in vivo.28 Akt is a serine/threonine
kinase that acts downstreamof growth factors, such as insulin,
and upstream of mTORC1. Akt increases signaling of mTORC1
but there are multiple feedback mechanisms to Akt, including
inhibitory feedback via p-S6 and activating feedback via
mTORC2.29 mTOR is present in human and animal placentas
and placental mTOR dysregulation is implicated in animal
models of fetal growth restriction and overgrowth.30,31 Met-
formin’s effects on placental mTOR signaling as measured by
concentrations of these markers are unknown.
It is plausible that in our study the HFD increased pla-
cental p-Akt expression via upregulation of insulin/insulin
growth factor-1 receptor signaling and that metformin
(which inhibits mTORC1) exposure further increased p-Akt
expression via mTORC2 (►Fig. 1). We hypothesized that an
Table 1 Dam weight, litter size, and placental weight characteristics by treatment group
Group1 (CD þ CT)
n ¼ 5
Group 2 (CD þ MT)
n ¼ 5
Group 3 (HFD þ CT)
n ¼ 5
Group 4 (HFD þ MT)
n ¼ 5
Dam starting weight,
g (mean  SEM)
23.2 (0.34) 23.0 (0.39) 22.2 (0.58) 24.4 (0.93)
Litter Size,
n (median  IQR)
11 (11–11) 9 (9–9) 10 (9–10) 10 (9–11)
Mean placenta weight,
g (mean  SEM)
0.088 (0.010) 0.072 (0.003) 0.10 (0.004) 0.092 (0.005)
Abbreviations: CD, control diet; HFD, high-fat diet; CT, control; MT, metformin; SEM, standard error of themean; IQR, interquartile range (compared
with pairwise Student’s t-test).
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HFDwould increase p-S6, a downstream product of mTORC1
which is responsible for increased protein translation and
cell growth. P-S6, however, was not increased among control
treatment micewhen an HFDwas added. Thus, in our model,
increase in fetal weight is not associated with the increased
mTORC1 signaling as a result of the HFD exposure. Among
dams exposed to an HFD, however, p-S6 was decreased as a
result of metformin exposure. This suggests that metformin
inhibition ofmTORC1 signalingonlyoccurred in the presence
of an HFD exposure.
We hypothesized that an HFD alone would increase
downstream markers of mTOR (p-S6) based upon other
work that showed that maternal diabetes promoted down-
stream mTOR signaling in rabbit preimplantation
embryos.30 Our finding that an HFD alone did not increase
placental p-S6 expression may be due to differences in the
models used (HFD vs. diabetic model), tissues studied
(placenta vs. embryo), and duration of the exposures
(17.5 days). mTORC1 receives inputs from at least five extra-
and intracellular signals: growth factors, stress, energy
status, oxygen, and amino acids.17 It’s possible that an
HFD for 17.5 days was not sufficient (either in terms of
the diet composition or the duration of the exposure) to
significantly affect mTOR1 signaling.
Our animalfindings are in contrast to results froma recent
double-blind, placebo-controlled randomized trial of met-
formin versus placebo in obese pregnant women. In this trial,
compared with placebo, metformin resulted in less maternal
weight gain but no significant differences in neonatal birth
weight.16 Explanations for this difference may be a lack of
control of dietary intake in the clinical trial and effects of
other environmental exposures and dietary exposures that
were not measured in the trial. Additionally, the trial
enrolled women with a body mass index > 35, and thus
themetabolic exposurewas obesity and not a high-fat diet or
excessive GWG.
Our study has several strengths. Wewere able to measure
the effects of an HFD and metformin in well-timed and
characterized pregnancies. The diets that the mice received
were standardized.Wewere also able to demonstrate that an
Fig. 2 Western blot analysis of placental expression of p-Akt, by treatment group. p < 0.001, p < 0.0001. CD, control diet; CT, control
treatment; HFD, high-fat diet; MT, metformin treatment.
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HFD exposure that began at the onset of pregnancy signifi-
cantly increased damand fetalweight without the confound-
ing effects of maternal obesity.
The limitations of our study include that it was not a
diabetes or obesity model which may have more direct
clinical application. This may have limited our ability to
detect differences in mTOR signaling as a result of a chronic
obesity exposure. In addition, an HFDmay affect and activate
mTOR signaling differently than a diet high in sugar, protein,
or total calories. Finally, the number of dams and placentas
from each group (five) may have limited our ability to detect
differences in damweight gain or mTOR signaling as a result
of metformin exposure.
Metformin is widely prescribed in pregnancy to treat both
pre-existing diabetes and gestational diabetes. It is generally
thought to be safe but few randomized trials have assessed
its short-term and long-term effects on offspring. The pos-
sibility that it may augment placental mTOR signaling as a
result of different maternal metabolic exposures warrants
additional research on its effects in pregnancy.
Conclusion
In conclusion, in ourmousemodel, placental expression of p-
Akt was increased as a result of both HFD and metformin
exposures. Among control treatment mice, placental p-S6
expression was similar between CD and HFD-fed mice.
However, placental p-S6 expression was decreased in those
placentas exposed to both an HFD andmetformin, compared
with those exposed to HFD alone. This pattern suggests that
increases in fetal weight are not associated with increased
mTORC1 signaling as a result of the HFD exposure. Among
dams exposed to an HFD, however, p-S6 was decreased as a
result of metformin exposure. This suggests that metformin
inhibition ofmTORC1 signalingonlyoccurred in the presence
of an HFD exposure. We theorize that in this model, an HFD
did not activate mTOR pathway signaling but metformin
appears to have inhibited mTOR pathway signaling in the
presence of an HFD and, in doing so, reduced fetal weight.20
As the nutrient-sensing capabilities of placental mTOR and
its effects on fetal growth continue to be studied, the role that
Fig. 3 Western blot analysis of placental expression of p-S6, by treatment group. p ¼ 0.001; CD, control diet; CT, control treatment; HFD,
high-fat diet; MT, metformin treatment.
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metformin may play as a placental mTOR pathway inhibitor
should continue to be explored.
Presentation
Presented, in part, in poster format at the Society for
Maternal Fetal Medicine’s 37th Annual Pregnancy Meet-
ing, January 27, 2017, Las Vegas, NV.
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